EMEA-003051-PIP01-21 - paediatric investigation plan

Depemokimab

Key facts

• Active Substance:
  Depemokimab
• Therapeutic area:
  Pneumology-allergology
• Decision number:
  P/0417/2021
• PIP number:
  EMEA-003051-PIP01-21
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of nasal polyposis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  29/10/2021

Decision

P/0417/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for depemokimab (EMEA-003051-PIP01-21)

AdoptedReference Number: EMA/522277/2021